Ishita Drugs

Why is Ishita Drugs & Industries Ltd falling/rising?

As of 21-Jul, Ishita Drugs & Industries Ltd's stock is at 71.04, down 1.04%, and has underperformed the sector. It is trading below all major moving averages, indicating a bearish trend, with a year-to-date decline of 11.20%.

As of 21-Jul, Ishita Drugs & Industries Ltd's stock price is falling, currently at 71.04, reflecting a change of -0.75, or -1.04%. The stock has underperformed compared to the sector by 1.34% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has decreased by 4.00%, while the benchmark Sensex has gained 0.54%. Year-to-date, the stock has declined by 11.20%, compared to a smaller decline of 9.09% in the Sensex. Additionally, despite a slight increase in delivery volume by 8.39% against the 5-day average, the overall performance suggests a lack of strong positive momentum, contributing to the stock's downward movement.

Which are the latest news on Ishita Drugs?

How big is Ishita Drugs?

As of 10th June, Ishita Drugs & Industries Ltd has a market capitalization of 22.00 Cr, with recent net sales of 14.67 Cr and a net profit of 0.78 Cr. The company reported shareholder's funds of 10.79 Cr and total assets of 16.30 Cr for the annual period ending in March 2025.

As of 10th June, Ishita Drugs & Industries Ltd has a market capitalization of 22.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Ishita Drugs reported Net Sales of 14.67 Cr and a Net Profit of 0.78 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds of 10.79 Cr and Total Assets amounting to 16.30 Cr.

Who are in the management team of Ishita Drugs?

The management team of Ishita Drugs consists of Jagdish Agrawal (Managing Director), Govind Gupta, Abha Agrawal (Non-Executive Director), Niranjan Agrawal, and Arvind Sapkal (Directors).

The management team of Ishita Drugs includes the following individuals:<BR><BR>1. Jagdish Agrawal - Managing Director<BR>2. Govind Gupta - Director<BR>3. Abha Agrawal - Non-Executive Director<BR>4. Niranjan Agrawal - Director<BR>5. Arvind Sapkal - Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

Who are the peers of the Ishita Drugs?

Ishita Drugs' peers include Guj. Terce Labs, Shree Ganesh Bio, Venmax Drugs, Centuple Global, and others. Most peers exhibit below-average management and growth risks, with Centuple Global showing the highest 1-year return at 105.84%, while Ishita Drugs has a return of -1.56%.

Peers: The peers of Ishita Drugs are Guj. Terce Labs., Shree Ganesh Bio, Venmax Drugs, Centuple Global, Desh Rakshak, Parmax Pharma, Cian Healthcare, Dipna Pharmachem, Mono Pharmacare, and Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at Guj. Terce Labs., Shree Ganesh Bio, Ishita Drugs, Venmax Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, Dipna Pharmachem, and Mono Pharmacare, while Good management risk is found at Centuple Global. Below Average growth is noted at Guj. Terce Labs., Shree Ganesh Bio, Ishita Drugs, Venmax Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, and Mono Pharmacare, while Excellent growth is observed at Dipna Pharmachem and Good growth at Centuple Global and Parmax Pharma. Good capital structure is present at Shree Ganesh Bio, Ishita Drugs, and Centuple Global, while Below Average capital structure is seen at Guj. Terce Labs., Venmax Drugs, Desh Rakshak, Parmax Pharma, Cian Healthcare, Dipna Pharmachem, Mono Pharmacare, and Medicamen Organ.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centuple Global at 105.84%, while the peer with the lowest is Dipna Pharmachem at -66.76%. Ishita Drugs has a 1-year return of -1.56%, which is better than Dipna Pharmachem but worse than Centuple Global. Additionally, the six-month return is negative for Guj. Terce Labs., Venmax Drugs, Centuple Global, Dipna Pharmachem, and Medicamen Organ.

What does Ishita Drugs do?

Ishita Drugs & Industries Ltd manufactures Active Pharmaceutical Ingredients, drug intermediates, fine chemicals, and excipients. As of March 2026, it reported net sales of 3 Cr and a market cap of INR 22 Cr.

Overview:<BR>Ishita Drugs & Industries Ltd is engaged in the manufacture of various Active Pharmaceutical Ingredients, drug intermediates, fine chemicals, and excipients, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Ishita Drugs & Industries Ltd was incorporated in February 1992 by Jagdish Agarwal. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 22 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.41<BR>- Return on Equity: 7.23%<BR>- Price to Book: 2.05<BR><BR>Contact Details:<BR>Address: Survey No 179/1 Taluka Sanand, Village Vasna-Iyava Ahmedabad Gujarat : 382170<BR>Email: ishitadrugs@vsnl.net<BR>Website: http://www.ishitadrugs.com

Should I buy, sell or hold Ishita Drugs & Industries Ltd?

Are Ishita Drugs & Industries Ltd latest results good or bad?

Ishita Drugs & Industries Ltd's latest results are largely negative, showing a 37.93% year-on-year decline in net profit and a 32.89% drop in net sales, leading to a 6.77% decrease in stock price post-announcement. While there are some positive aspects, such as a debt-free balance sheet, the overall performance raises concerns about the company's future prospects.

Ishita Drugs & Industries Ltd's latest results present a mixed picture, leaning more towards negative. In Q4 FY26, the company reported a net profit of ₹0.18 crore, which is a 12.50% increase quarter-on-quarter. However, this represents a significant decline of 37.93% compared to the same quarter last year. <BR><BR>Net sales for the same quarter were ₹3.06 crore, down 2.55% from the previous quarter and a steep 32.89% year-on-year. This ongoing revenue contraction is concerning, especially given the volatility in sales over recent quarters, which has seen significant fluctuations.<BR><BR>Operating margins have also deteriorated, falling to 3.27%, down from 4.46% in the previous quarter and 6.36% a year ago. This decline indicates increasing cost pressures that the company is struggling to manage.<BR><BR>Despite a debt-free balance sheet and a relatively attractive valuation compared to industry peers, the market reacted negatively to these results, with the stock price declining by 6.77% after the announcement. Investors are likely worried about the company's declining revenue trajectory and operational challenges.<BR><BR>Overall, while there are some positive aspects, such as the improvement in profit margins due to other income, the overall performance indicates significant operational headwinds and raises concerns about the company's future prospects.

How has been the historical performance of Ishita Drugs?

Ishita Drugs has shown mixed historical performance, with net sales slightly decreasing to 15.00 Cr in March 2025 but profit metrics improving, including a profit after tax of 0.87 Cr and an EPS of 2.91. However, cash flow from operating activities turned negative at -3.00 Cr, indicating challenges in cash generation.

Answer:<BR>The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 2024, while total liabilities also rose to 16.30 Cr, reflecting a significant increase in short-term borrowings to 3.81 Cr. The cash flow from operating activities showed a negative trend with -3.00 Cr in March 2025, down from 2.00 Cr in March 2024, indicating challenges in cash generation despite the growth in profits.

When is the next results date for Ishita Drugs?

Ishita Drugs will announce its results on 12 August 2025.

Ishita Drugs will declare its results on 12 August 2025.

Is Ishita Drugs overvalued or undervalued?

As of June 2, 2025, Ishita Drugs is considered undervalued with a PE ratio of 24.07 and strong ROCE of 39.71%, outperforming peers like Sun Pharma and Divi's Lab, and has achieved a 1-year return of 23.56%, significantly higher than the Sensex's 7.60%.

As of 2 June 2025, Ishita Drugs has moved from a fair to an attractive valuation grade, indicating a shift in market perception. The company appears to be undervalued, with a PE ratio of 24.07, an EV to EBIT of 16.19, and a ROCE of 39.71%. In comparison to its peers, Ishita Drugs is more favorably positioned than Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, which shows a PE of 79.33, both of which are considered expensive.<BR><BR>Additionally, while peers like Cipla and Dr. Reddy's Labs have attractive valuations with PE ratios of 22.99 and 19.49 respectively, Ishita Drugs' strong ROCE and competitive PEG ratio of 1.47 suggest it is well-positioned for growth relative to its industry. Recent stock performance has also outpaced the Sensex, with a 1-year return of 23.56% compared to the Sensex's 7.60%, reinforcing the notion that Ishita Drugs is undervalued in the current market context.

What is the technical trend for Ishita Drugs?

As of June 3, 2025, Ishita Drugs shows a mildly bearish trend, with bearish weekly MACD and moving averages, while mixed signals from KST and Bollinger Bands suggest potential for future gains.

As of 3 June 2025, the technical trend for Ishita Drugs has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The daily moving averages are also mildly bearish, reinforcing the current trend. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals. The Bollinger Bands indicate a sideways movement on the weekly timeframe but are bullish on the monthly, which could imply potential for future gains. Overall, the current technical stance is mildly bearish, driven primarily by the bearish MACD and moving averages, with some conflicting signals from the KST and Bollinger Bands.

Who are the top shareholders of the Ishita Drugs?

The top shareholders of Ishita Drugs include Umang Financial Services Limited with 9.94%, and Mahendra Girdharilal Wadhwani, the largest public shareholder at 2.15%. Individual investors hold a combined 46.89%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Ishita Drugs include Umang Financial Services Limited, which holds the highest promoter stake at 9.94%. In terms of public shareholders, Mahendra Girdharilal Wadhwani is the largest, with a holding of 2.15%. Additionally, individual investors collectively hold a significant portion, accounting for 46.89% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Has Ishita Drugs declared dividend?

No Dividend History Available